Clinical Trial Update: Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating capecitabine (XELODA) with or without lapatinib (GW572016) in women with refractory advanced or metastatic breast cancer has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED